These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33859800)

  • 1. Discovery of the First Orally Available, Selective K
    Griffin AM; Kahlig KM; Hatch RJ; Hughes ZA; Chapman ML; Antonio B; Marron BE; Wittmann M; Martinez-Botella G
    ACS Med Chem Lett; 2021 Apr; 12(4):593-602. PubMed ID: 33859800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule inhibitors of Slack potassium channels as potential therapeutics for childhood epilepsies.
    M Qunies A; A Emmitte K
    Pharm Pat Anal; 2022 Mar; 11(2):45-56. PubMed ID: 35369761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. K
    Gertler TS; Cherian S; DeKeyser JM; Kearney JA; George AL
    Neurobiol Dis; 2022 Jun; 168():105713. PubMed ID: 35346832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired motor skill learning and altered seizure susceptibility in mice with loss or gain of function of the Kcnt1 gene encoding Slack (K
    Quraishi IH; Mercier MR; McClure H; Couture RL; Schwartz ML; Lukowski R; Ruth P; Kaczmarek LK
    Sci Rep; 2020 Feb; 10(1):3213. PubMed ID: 32081855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Epilepsy of Infancy With Migrating Focal Seizures: Identification of
    Mao X; Bruneau N; Gao Q; Becq H; Jia Z; Xi H; Shu L; Wang H; Szepetowski P; Aniksztejn L
    Front Cell Neurosci; 2020; 14():1. PubMed ID: 32038177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico model reveals the key role of GABA in KCNT1-epilepsy in infancy with migrating focal seizures.
    Kuchenbuch M; Nabbout R; Yochum M; Sauleau P; Modolo J; Wendling F; Benquet P
    Epilepsia; 2021 Mar; 62(3):683-697. PubMed ID: 33617692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting K
    Cole BA; Clapcote SJ; Muench SP; Lippiat JD
    Trends Pharmacol Sci; 2021 Aug; 42(8):700-713. PubMed ID: 34074526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Activity Relationship Studies in a Series of Xanthine Inhibitors of SLACK Potassium Channels.
    Qunies AM; Spitznagel BD; Du Y; Peprah PK; Mohamed YK; Weaver CD; Emmitte KA
    Molecules; 2024 May; 29(11):. PubMed ID: 38893312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Phe932Ile mutation in KCNT1 channels associated with severe epilepsy, delayed myelination and leukoencephalopathy produces a loss-of-function channel phenotype.
    Evely KM; Pryce KD; Bhattacharjee A
    Neuroscience; 2017 May; 351():65-70. PubMed ID: 28366665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KCNT1-related epilepsies and epileptic encephalopathies: phenotypic and mutational spectrum.
    Bonardi CM; Heyne HO; Fiannacca M; Fitzgerald MP; Gardella E; Gunning B; Olofsson K; Lesca G; Verbeek N; Stamberger H; Striano P; Zara F; Mancardi MM; Nava C; Syrbe S; Buono S; Baulac S; Coppola A; Weckhuysen S; Schoonjans AS; Ceulemans B; Sarret C; Baumgartner T; Muhle H; Portes VD; Toulouse J; Nougues MC; Rossi M; Demarquay G; Ville D; Hirsch E; Maurey H; Willems M; de Bellescize J; Altuzarra CD; Villeneuve N; Bartolomei F; Picard F; Hornemann F; Koolen DA; Kroes HY; Reale C; Fenger CD; Tan WH; Dibbens L; Bearden DR; Møller RS; Rubboli G
    Brain; 2021 Dec; 144(12):3635-3650. PubMed ID: 34114611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of a novel series of 1,2,4-oxadiazole inhibitors of SLACK potassium channels: Identification of in vitro tool VU0935685.
    Qunies AM; Spitznagel BD; Du Y; David Weaver C; Emmitte KA
    Bioorg Med Chem; 2023 Nov; 95():117487. PubMed ID: 37812884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-causing Slack potassium channel mutations produce opposite effects on excitability of excitatory and inhibitory neurons.
    Wu J; Quraishi IH; Zhang Y; Bromwich M; Kaczmarek LK
    Cell Rep; 2024 Mar; 43(3):113904. PubMed ID: 38457342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Patients With KCNT1-Related Epilepsy Responding to Phenobarbital and Potassium Bromide.
    Datta AN; Michoulas A; Guella I; ; Demos M
    J Child Neurol; 2019 Oct; 34(12):728-734. PubMed ID: 31208268
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical and molecular characterization of
    McTague A; Nair U; Malhotra S; Meyer E; Trump N; Gazina EV; Papandreou A; Ngoh A; Ackermann S; Ambegaonkar G; Appleton R; Desurkar A; Eltze C; Kneen R; Kumar AV; Lascelles K; Montgomery T; Ramesh V; Samanta R; Scott RH; Tan J; Whitehouse W; Poduri A; Scheffer IE; Chong WKK; Cross JH; Topf M; Petrou S; Kurian MA
    Neurology; 2018 Jan; 90(1):e55-e66. PubMed ID: 29196579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized Therapy.
    Dilena R; DiFrancesco JC; Soldovieri MV; Giacobbe A; Ambrosino P; Mosca I; Galli MA; Guez S; Fumagalli M; Miceli F; Cattaneo D; Darra F; Gennaro E; Zara F; Striano P; Castellotti B; Gellera C; Varesio C; Veggiotti P; Taglialatela M
    Neurotherapeutics; 2018 Oct; 15(4):1112-1126. PubMed ID: 30112700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New use for an old drug: quinidine in KCNT1-related epilepsy therapy.
    Liu R; Sun L; Wang Y; Wang Q; Wu J
    Neurol Sci; 2023 Apr; 44(4):1201-1206. PubMed ID: 36437393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligonucleotide therapy for KCNT1 encephalopathy.
    Burbano LE; Li M; Jancovski N; Jafar-Nejad P; Richards K; Sedo A; Soriano A; Rollo B; Jia L; Gazina EV; Piltz S; Adikusuma F; Thomas PQ; Kopsidas H; Rigo F; Reid CA; Maljevic S; Petrou S
    JCI Insight; 2022 Dec; 7(23):. PubMed ID: 36173683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KCNT1 epilepsy with migrating focal seizures shows a temporal sequence with poor outcome, high mortality and SUDEP.
    Kuchenbuch M; Barcia G; Chemaly N; Carme E; Roubertie A; Gibaud M; Van Bogaert P; de Saint Martin A; Hirsch E; Dubois F; Sarret C; Nguyen The Tich S; Laroche C; des Portes V; Billette de Villemeur T; Barthez MA; Auvin S; Bahi-Buisson N; Desguerre I; Kaminska A; Benquet P; Nabbout R
    Brain; 2019 Oct; 142(10):2996-3008. PubMed ID: 31532509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in KCNT1 cause a spectrum of focal epilepsies.
    Møller RS; Heron SE; Larsen LH; Lim CX; Ricos MG; Bayly MA; van Kempen MJ; Klinkenberg S; Andrews I; Kelley K; Ronen GM; Callen D; McMahon JM; Yendle SC; Carvill GL; Mefford HC; Nabbout R; Poduri A; Striano P; Baglietto MG; Zara F; Smith NJ; Pridmore C; Gardella E; Nikanorova M; Dahl HA; Gellert P; Scheffer IE; Gunning B; Kragh-Olsen B; Dibbens LM
    Epilepsia; 2015 Sep; 56(9):e114-20. PubMed ID: 26122718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KCNT1 mutations in seizure disorders: the phenotypic spectrum and functional effects.
    Lim CX; Ricos MG; Dibbens LM; Heron SE
    J Med Genet; 2016 Apr; 53(4):217-25. PubMed ID: 26740507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.